6-K
PolyPid Ltd. (PYPD)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of: May 2021 (Report No. 2)
Commission File Number: 001-38428
PolyPid Ltd.
(Translation of registrant’s name intoEnglish)
18 Hasivim Street
Petach Tikva 495376, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
CONTENTS
Attached hereto and incorporated herein is the Registrant’s press release issued on May 12, 2021, titled “PolyPid Ltd. Reports First Quarter 2021 Financial Results and Provides Corporate Update.”
The bullet points under the section titled “Recent Corporate Highlights,” the sections titled “Financial Results for Three Months Ended March 31, 2021,” and “Forward-Looking Statements” and the GAAP financial statements in the press release are incorporated by reference into the Registrant’s Registration Statement on Form S-8 (Registration No. 333-239517), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
| Exhibit No. | |
|---|---|
| 99.1 | Press Release issued by PolyPid Ltd. on May 12, 2021, titled “PolyPid Ltd. Reports First Quarter 2021 Financial Results and Provides Corporate Update.” |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| POLYPID LTD. | |||
|---|---|---|---|
| Date: May 12, 2021 | By: | /s/ Dikla Czaczkes Akselbrad | |
| Name: | Dikla Czaczkes Akselbrad | ||
| Title: | Executive Vice President and<br><br>Chief Financial Officer |
2
Exhibit 99.1
PolyPid Ltd. Reports First Quarter 2021 FinancialResults andProvides Corporate Update
● Recruitment Progressing as Planned with Nearly 200 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in AbdominalSurgery
● Recruitment Rate in SHIELD I trial Doubled in the Last Three Weeks
● Manufacturing Facility Now Fully Scaled Up and Capable of Supporting at Least First 30 Months of Anticipated Commercial Demand forD-PLEX100
● Conference Call Schedule**d for Today at 8:30 AM ET
PETAHTIKVA, Israel, May 12, 2021 -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today provided a corporate update and reported financial results for the three months ended March 31, 2021.
RecentCorporate Highlights:
| ● | Recruitment<br> progressing as planned with nearly 200 patients enrolled into the ongoing Phase 3 SHIELD<br> I (Surgical<br> site Hospital-acquired Infection<br> PrEvention with Local D-plex)<br> study, the first of two ongoing Phase 3 clinical trials of the Company’s lead product<br> candidate D-PLEX100, for the prevention of surgical site infections (SSIs) in<br> abdominal surgery (soft tissue). |
|---|---|
| ● | The<br> Company plans to enroll 616-900 patients undergoing high priority operations in 60 centers<br> in the United States,<br> Europe and Israel. Following<br> the enrollment of approximately 500 patients, the study design provides for a blinded sample<br> size re-estimation. |
| --- | --- |
| ● | Enrollment<br> is also advancing as anticipated in SHIELD II, the second of two Phase 3 clinical trials<br> for D-PLEX100 in abdominal surgery (soft<br> tissue). SHIELD II will enroll approximately 900-1,400 patients across 60 centers<br> in the United States, Europe and Israel<br> and has broader eligibility criteria, including minimally invasive surgical procedures. |
| --- | --- |
| ● | Manufacturing<br> facility is now fully scaled up and capable of producing the first 30 months of anticipated<br> commercial demand for D-PLEX100. |
| --- | --- |
| ● | Continued<br> to generate compelling preclinical data from the Company’s new OncoPLEX intra-tumoral<br> cancer therapy program. OncoPLEX utilizes PolyPid’s<br> PLEX technology in the intra-operative tumor resection setting to provide prolonged and controlled<br> exposure to docetaxel within the tumor resected site, which is important to prevent local<br> tumor recurrence and the potential spreading of cancer cells. |
| --- | --- |
“We have made significant progress advancing our promising development programs and continuing our evolution towards successful commercialization,” said Amir Weisberg, PolyPid’s Chief Executive Officer. “Our robust Phase 3 trials for D-PLEX100 for the prevention of SSIs, SHIELD I and SHIELD II, continue to enroll patients at the expected rate. To this end, we are thrilled to report that the recruitment rate in SHIELD I trial doubled in the last three weeks and that we have now enrolled nearly 200 patients in the trial. We continue to anticipate the availability of top-line results for SHIELD I by year-end 2021 and top-line results from SHIELD II by the end of next year.”
“We also continue to generate additional compelling preclinical data with OncoPLEX, including positive safety data in a promising solid tumor indication,” continued Mr. Weisberg. “We are excited to further progress our OncoPLEX development program and potentially initiate a first-in-man Phase 1 clinical trial in 2022.”
“Our strong balance sheet continues to drive our robust clinical development program. Our cash runway extends into 2022 and we remain well-positioned to complete the SHIELD I study and conduct SHIELD II, as well as prepare for the submission of a New Drug Application to the FDA with cash on hand,” concluded Mr. Weisberg.
Financialresults for three months ended March 31, 2021
| ● | Research<br> and development expenses for the three months ended March 31, 2021 were $6.0 million, compared<br> to $3.4 million in the same three-month period of 2020, as spending increased due to the<br> ongoing SHIELD I and SHIELD II Phase 3 clinical trials in abdominal surgery. |
|---|---|
| ● | Marketing<br> and business development expenses for the three months ended March 31, 2021 were $0.7 million,<br> compared to $0.3 million for the same period of 2020, as spending increased primarily due<br> to additional marketing and business development personnel hired in the Company’s New<br> Jersey offices. |
| --- | --- |
| ● | General<br> and administrative expenses for the three months ended March 31, 2021 were $2.1 million,<br> compared to $0.7 million for the same period of 2020. This increase was due to the increase<br> in costs due to the Company’s status as a publicly traded company with higher D&O<br> insurance costs and an increase in non-cash share-based compensation. |
| --- | --- |
| ● | For<br> the three months ended March 31, 2021, the Company had a net loss attributable<br> to ordinary shares of $8.7 million, compared to a net loss of $5.9 million, in<br> the three-month period ended March 31, 2020. |
| --- | --- |
| ● | As<br> of March 31, 2021, the Company had cash and cash equivalents, short-term deposits<br> and long-term deposits in the amount of $61.4 million, compared to $66.6 million at December<br> 31, 2020. PolyPid continues to expect that this cash balance will be sufficient to fund operations<br> into 2022*.* |
| --- | --- |
ConferenceCall Dial-In & Webcast Information:
| Date: | Wednesday, May 12, 2021 |
|---|---|
| Time: | 8:30 AM Eastern Time |
| United States: | +1 877-870-9135 |
| Israel: | +972 1809 213-985 |
| International: | +44 (0) 2071 928338 |
| Conference ID: | 7258907 |
| Webcast: | https://edge.media-server.com/mmc/p/j63c5h43 |
About D-PLEX100
PolyPid’s lead product candidate, D-PLEX100, is a novel drug product candidate designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs. Following the administration of D-PLEX100 into the surgical site, the PLEX technology enables a prolonged and constant release of the broad-spectrum antibiotic doxycycline, resulting in high local concentration of the drug for a period of four weeks for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. D-PLEX100 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of SSIs in patients undergoing elective colorectal surgery. D-PLEX100 has also received two Qualified Infectious Disease Product (QIDP) designations as well as two Fast Track designations for the prevention of post-abdominal surgery incisional infection and for the prevention of sternal wound infection post-cardiac surgery.
2
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics. PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with medications, enables precise delivery of drugs at effective release rates, over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of sternal and abdominal surgical site infections (SSIs).
For additional company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.
Forward-looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses statements relating to the expected recruitment for trials, timing of trials and release of the results thereof, the capacity of the Company’s manufacturing facility, the potential benefits of PLEX and OncoPLEX, the sufficiency of the Company’s cash to fund future operations, and all statements (other than statements of historical facts) that address activities, events, or developments that the Company intends, expects, projects, believes, or anticipates will or may occur in the future. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed on March 5, 2021. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.
References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.
Contacts:
PolyPid, Ltd.
Dikla Czaczkes Akselbrad
EVP & CFO
Tel: +972-747195700
Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com
3
CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands
| March 31, | December 31, | |||
|---|---|---|---|---|
| 2021 | 2020 | |||
| Unaudited | Audited | |||
| U.S. dollars in thousands | ||||
| ASSETS | ||||
| CURRENT ASSETS: | ||||
| Cash and cash equivalents | $ | 5,993 | $ | 4,319 |
| Restricted cash | 385 | 390 | ||
| Short-term deposits | 43,279 | 40,157 | ||
| Prepaid expenses and other receivables | 1,286 | 2,334 | ||
| Total current assets | 50,943 | 47,200 | ||
| LONG-TERM ASSETS: | ||||
| Property and equipment, net | 6,023 | 5,890 | ||
| Long-term deposits | 12,100 | 22,120 | ||
| Other long-term assets | 773 | 637 | ||
| Total long-term assets | 18,896 | 28,647 | ||
| Total assets | 69,839 | 75,847 |
4
CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands (except share and per share data)
| March 31, | December 31, | |||||
|---|---|---|---|---|---|---|
| 2021 | 2020 | |||||
| Unaudited | Audited | |||||
| U.S. dollars in thousands | ||||||
| LIABILITIES, CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS’ EQUITY | ||||||
| CURRENT LIABILITIES: | ||||||
| Trade payables | $ | 1,468 | $ | 974 | ||
| Other payables and accrued expenses | 2,038 | 1,903 | ||||
| Total current liabilities | 3,506 | 2,877 | ||||
| Long-term liabilities: | ||||||
| Other liabilities | 186 | 193 | ||||
| Total long-term liabilities | 186 | 193 | ||||
| Commitments and Contingencies | ||||||
| Shareholders’ equity: | ||||||
| Share capital - | ||||||
| Ordinary shares with no par value - Authorized: 47,800,000 shares at March 31, 2021 (unaudited) and December 31, 2020; Issued and outstanding: 18,745,142 and 18,494,739 shares at March 31, 2021 (unaudited) and December 31, 2020, respectively. | - | - | ||||
| Additional paid-in capital | 207,120 | 205,063 | ||||
| Accumulated deficit | (140,973 | ) | (132,286 | ) | ||
| Total shareholders’ equity | 66,147 | 72,777 | ||||
| Total liabilities, convertible preferred shares and shareholders’ equity | $ | 69,839 | $ | 75,847 |
5
CONSOLIDATED STATEMENTS OF OPERATIONS
U.S. dollars in thousands (except share and per share data)
| Three months ended<br> <br>March 31, | |||||
|---|---|---|---|---|---|
| 2021 | 2020 | ||||
| Unaudited | |||||
| U.S. dollars in thousands | |||||
| Operating expenses: | |||||
| Research and development, net | $ | 6,018 | $ | 3,433 | |
| Marketing and business development expenses | 652 | 276 | |||
| General and administrative | 2,127 | 727 | |||
| Operating loss | 8,797 | 4,436 | |||
| Financial expense (income), net | (110 | ) | 1,433 | ||
| Net loss | $ | 8,687 | $ | 5,869 | |
| Net loss attributable to Ordinary shares | $ | 8,687 | $ | 5,869 | |
| Basic and diluted net loss per Ordinary share | $ | 0.47 | $ | 13.90 | |
| Weighted average number of Ordinary shares used in computing basic and diluted net loss per share | 18,623,154 | 562,748 |
6